Research
Hormonal
Semaglutide (2.4 mg once weekly) produces a mean weight loss of 14.9% over 68 weeks in patients with obesity without diabetes.
If you are prescribed Semaglutide (Wegovy), expect to take a 2.4 mg injection once weekly. This can lead to a 14.9% reduction in body weight over 68 weeks. Be prepared for potential gastrointestinal side effects like nausea, which can often be managed by eating smaller meals.
GoodSupportsHIGH confidence
Compared to placebo, patients in the treatment group (semaglutide 2.4 mg) were able to achieve a 14.9% reduction in body weight compared to 2.4% with placebo at 68 weeks.
Why this rating
Based on the STEP trial.
Source
Medical Management of Obesity: Current Trends and Future Perspectives
Andrés Calderón et al. · Methodist DeBakey Cardiovascular Journal · 2025
DOI 10.14797/mdcvj.1503
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Tirzepatide (15 mg once weekly) combined with lifestyle counseling produces a mean weight loss of 20.9% over 72 weeks in patients with obesity or overweight.Good
- Liraglutide (3 mg once daily) produces a mean weight loss of 8% over 56 weeks in patients without diabetes.Good
- GLP-1 and GIP receptor agonists reduce the composite incidence of death due to cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke in patients with overweight or obesity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →